News | October 29, 2010

Study Site Enrollment Completed for EP Device Antibacterial Envelope

October 29, 2010 – Site enrollment has been completed for the 50-site CITADEL and CENTURION clinical studies to evaluate the Tyrx AigisRx Antibacterial Envelope. The device is designed to help reduce surgical-site infections (SSIs) associated with cardiac implantable electronic devices (CIEDs).

The trials are both large, prospective, multicenter clinical studies, which together, will enroll 4,300 subjects at 50 clinical study sites across the United States. Patients enrolled in these studies have a pacemaker, implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device that will be replaced with an ICD or CRT device accompanied by AigisRx.

In the CITADEL study, prospectively enrolled patients receiving AigisRx will be compared to published controls who have undergone pacemaker, ICD or CRT device replacement with an ICD without AigisRx.

In the CENTURION study, prospectively enrolled patients will be compared to 2000 case-matched controls that have undergone pacemaker, ICD or CRT device replacement with a CRT without AigisRx.
The primary endpoints for both studies will be 1) major ICD/CRT device-related infections and 2) ICD/CRT device-related mechanical complications. Patients will be followed for 12 months, with predefined interim analyses at three and six months.

The AigisRx Envelope is an antibacterial mesh envelope designed to deliver antimicrobial agents which help provide protection against infections associated with implanted pacemakers and ICDs/CRTs. AigisRx also securely holds a pacemaker or ICD/CRT in order to create a stable environment when implanted in the body.

“Published data shows us that the risk of CIED infection is higher for ICDs/CRTs in comparison to pacemakers. Additionally, replacement procedures carry more infection risk compared to initial implants. The CITADEL and CENTURION studies will provide vital information on the clinical performance of AIGISRx in these particularly high risk groups for CIED infection,” said Scott Burkett, M.D., FACP, FACC, Burkett Heart Clinic, Monroe, La.

Tyrx commercializes innovative, implantable combination drug/device products focused on infection control, including the AigisRx Antibacterial Envelope and AigisRx Flat Sheet products. Their products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac implantable electronic device (CIED)-related endocarditis, including “superbugs” or MRSA.

For more information:

Related Content

FDA Warns of Premature Battery Depletion in Some Medtronic Pacemakers
News | Pacemakers | May 07, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) issued a safety communication to alert healthcare providers and patients...
Artificial Intelligence Can Improve Emergency X-ray Identification of Pacemakers
News | Pacemakers | March 29, 2019
A research team from Imperial College London believes a new software could speed up the diagnosis and treatment of...
Medtronic Recalls Dual Chamber Pacemakers
News | Pacemakers | February 20, 2019
Medtronic is recalling its dual chamber implantable pulse generators (IPGs) due to the possibility of a software error...
CHLA/USC Team Designs Novel Micropacemaker

Model of the human heart with microprocessor located in the pericardial sac and attached to the left ventricle. Graphic courtesy of Business Wire.

News | Pacemakers | June 29, 2018
Investigators at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) have...
Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block
News | Pacemakers | May 24, 2018
Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist...
Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System Detects Atrial Contractions, Restores AV Synchrony
News | Pacemakers | May 24, 2018
New clinical study results demonstrate that an investigational algorithm, utilizing the accelerometer signal in the...
The Boston Scientific Essentio MRI-safe pacemaker.

The Boston Scientific Essentio MRI-safe pacemaker. It is common for pacemaker patients to need magnetic resonance imaging (MRI), which has not previously been possible because the magnetic fields could damage older devices. All pacemaker vendors now have FDA-cleared MRI compatible pacemakers. 

Feature | Pacemakers | February 13, 2018 | Dave Fornell
There have been several advancements in pacemaker technologies over the past few years.
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

Mexican government reports conclude more than half of the population does not have access to social security or private insurance that covers a pacemaker implant, and 44 percent live in poverty. Recycling donated, explanted pacemakers offers a new option for these patients.

News | Pacemakers | November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers | June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Videos | Pacemakers | May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Overlay Init